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Objective. Using biomarkers for early and accurate identiﬁcation of patients at low risk of serious illness may improve the ﬂow in the
emergency department (ED) by classifying these patients as nonurgent or even suitable for discharge. A potential biomarker for this
purpose is soluble urokinase plasminogen activator receptor (suPAR). We hypothesized that availability of suPAR might lead to a
higher proportion of early discharges. Design. A substudy of the interventional TRIAGE III trial, comparing patients with a valid
suPAR measurement at admission to those without. The primary endpoint was the proportion of patients discharged alive from
the ED within 24 hours. Secondary outcomes were length of hospital stay, readmissions, and mortality within 30 days. Setting.
EDs at two university hospitals in the Capital Region of Denmark. Participants. 16,801 acutely admitted patients were included.
Measurements and Main Results. The suPAR level was available in 7,905 patients (suPAR group), but not in 8,896 (control
group). The proportion of patients who were discharged within 24 hours of admittance was signiﬁcantly higher in the suPAR
group compared to the control group (50.2% (3,966 patients) vs. 48.6% (4,317 patients), P = 0 04). Furthermore, the mean
length of hospital stay in the suPAR group was signiﬁcantly shorter compared to that in the control group (4.3 days (SD 7.4) vs.
4.6 days (SD 9.4), P = 0 04). In contrast, the readmission rate within 30 days was signiﬁcantly higher in the suPAR group (10.6%
(839 patients) vs. 8.8% (785 patients), P < 0 001). Among patients discharged within 24 hours, there was no signiﬁcant
diﬀerence in the readmission rate or mortality within 30 days. Readmission occurred in 8.5% (336 patients) vs. 7.7% (331
patients) (P = 0 18) and mortality in 1.3% (52 patients) vs. 1.8% (77 patients) (P = 0 08) for the suPAR group and control group,
respectively. Conclusion. These post hoc analyses demonstrate that the availability of the prognostic biomarker suPAR was
associated with a higher proportion of discharge within 24 hours and reduced length of stay, but more readmissions. In patients
discharged within 24 hours, there was no diﬀerence in readmission or mortality. Trial Registration of the Main Trial. This trial
is registered with NCT02643459.
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1. Introduction
Early and accurate identiﬁcation of patients at low risk of
serious illness may improve the ﬂow in the emergency
department (ED) by classifying these patients as nonurgent
or even suitable for discharge [1, 2]. This would allow for a
better utilization of limited staﬀ and resources and could
potentially translate into improved patient outcomes. Pre-
vious research has suggested that blood-based prognostic
biomarkers measured at admittance can be used for this pur-
pose [3–9]. One of these prognostic biomarkers is soluble
urokinase plasminogen activator receptor (suPAR), which
was found in recent studies to be a strong and nonspeciﬁc
marker of the presence and severity of a wide range of dis-
eases and overall prognosis in ED patients, making suPAR
suitable for risk stratiﬁcation [3, 10–15].
The TRIAGE III trial investigated the eﬀect of intro-
ducing suPAR in the EDs for improving early risk stratiﬁca-
tion and as a clinical decision tool [16, 17]. Despite the good
abilities to discriminate between patients at high and low risk
of mortality, we found no eﬀect on all-cause mortality when
suPAR was introduced to enhance risk stratiﬁcation [17].
Here, we hypothesize that due to the nonspeciﬁc nature
of suPAR, the biomarker might be most appropriate for
identifying patients at very low risk. The aim of this post
hoc substudy of the TRIAGE III trial was to investigate
if availability of suPAR had an impact on discharge decisions
leading to a higher proportion of early discharges within 24
hours from the ED.
2. Materials and Methods
2.1. Setting and Design. In this post hoc substudy, we used the
data on the same consecutively included and unselected pop-
ulation as in the TRIAGE III trial. As early discharge based
on suPAR would require availability of the suPAR level, we
compared patients that had a valid suPAR measurement to
those without, regardless of whether patients arrived in inter-
ventional or control periods (Figure 1).
The protocol and primary results of the TRIAGE III trial
have been published previously [16, 17]. In brief, TRIAGE III
was a cluster-randomized interventional trial investigating
the eﬀect on mortality when suPAR was introduced in the
ED. In interventional periods, suPAR measurement was
available along with the routine blood tests at acute admis-
sion. Using the point-of-care equipment, “suPARnostic®
Quick Triage”, the suPAR results were shown to the ED staﬀ
on monitors and in the electronic patient records within 2
hours of admission. Prior to the TRIAGE III trial, doctors
at the EDs were informed about the prognostic ability of
suPAR through oral presentations, a brief review on the pub-
lished literature, and pocket cards. Two main advices were
given to the staﬀ: (1) if the suPAR level is elevated, the risk
of death is high and the patient should receive a high level
of attention and (2) if the suPAR level is low, the risk of
life-threatening disease and death is low and early discharge
of the patient should therefore be considered [16]. In control
periods, suPAR was not measured.
2.2. Data. Patients included in the TRIAGE III trial were
acutely admitted to one of the participating EDs. The ﬁrst
admission in the inclusion period was deﬁned as their index
admission, and only the index admission was included in the
analyses. Data on blood tests were extracted from the elec-
tronic hospital database via the Department of Clinical
Biochemistry. Routine blood tests included levels of albumin,
creatinine, C-reactive protein (CRP), and haemoglobin. We
acquired data on baseline characteristics, hospital admis-
sions, and death from the Danish National Registries. All
contacts at Danish hospitals, including dates of admission
and discharge and diagnoses, are registered in the Danish
National Patient Registry (DNPR), and the Danish Civil
Registration System contains information on sex, date of
birth, and vital status [18, 19]. The Charlson comorbidity
index (Charlson score) was calculated using a modiﬁed SAS
macro and based on all diagnoses in the DNPR that were
registered two years prior to the index admission [20].
2.3. Outcomes. We calculated the proportion of patients dis-
charged alive from the ED within 24 hours (early discharge),
the length of hospital stay, and the number of readmissions
within 30 days according to whether a valid suPAR level
was available at admission. Furthermore, to assess safety in
early discharge decisions associated with the suPAR level,
we calculated 30-day all-cause mortality adjusted for diﬀer-
ences in baseline variables along with 30-day readmission
rates of patients discharged within 24 hours. Finally, we
assessed the predictive ability of suPAR regarding 30-day
mortality and readmissions in patients discharged within
24 hours.
2.4. Statistical Analysis. Continuous variables are presented
as median and interquartile range (IQR), and categorical
variables as number (n) and percentages (%). Baseline char-
acteristics were compared using the chi-square test, Student’s
independent two-sample t-test, and Wilcoxon rank-sum
test. Mortality was compared using logistic regression and
Fisher’s exact test. Furthermore, mortality was assessed in a
multivariable logistic regression model adjusted for age, sex,
hospital, haemoglobin, and albumin levels and ﬁnally in a
model adjusted for all baseline variables, and results are pre-
sented as odds ratios (OR) with 95% conﬁdence intervals
(CI); in all analyses, the control group serves as the reference.
Kaplan-Meier plots were used to illustrate survival, and the
log-rank test was used to compare survival. Readmission
rates were reported as proportions and compared using Fish-
er’s exact test, additionally with a Cox model, where results
are presented as hazard ratios (HR) with CI. The predictive
ability of suPAR with regard to 30-day mortality was assessed
with the area under the curve (AUC) for receiver operating
characteristic (ROC) curves. Comparison of AUC between
diﬀerent models was done by the DeLong method [21].
P < 0 05 was considered statistically signiﬁcant. Statistics
was performed in R version 3.2.3 [22–24].
2.5. Ethics. The TRIAGE III trial was approved by the Danish
Data Protection Agency (HGH-2015-042, I-Suite no. 04087)
as well as the Danish Patient Safety Authority (Ref. no. 3-
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3013-1744/1). The trial was presented to the Regional Ethics
Committee who decided that no formal approval was needed
for the cluster-randomized TRIAGE III trial and that it could
be conducted without the consent of the patients in accor-
dance with the Danish law (Ref. no. FSP-15003590). No fur-
ther permissions were required for this substudy.
3. Results
3.1. Trial Population. All data of the post hoc analyses
were calculated on the basis of the TRIAGE III data set,
which included 26,653 acute admissions of 16,801 unique
patients. Patients were included in the TRIAGE III trial
from January 11, 2016, to June 6, 2016. The suPAR level
was available at the index admission in 7,905 patients
(suPAR group), and no value was available in 8,896 (control
group) (Figure 1 and Table S1). There were no missing data.
Baseline characteristics were comparable between the
groups; however, there was a signiﬁcant diﬀerence in the
range of the albumin and CRP levels. Table S2 compares
patients without a valid suPAR measurement arriving in
the intervention period (N = 1,002) and patients arriving
in the control period (N = 7,898). Apart from small but
signiﬁcant diﬀerences in the mean Charlson score (lower in
the control group) and levels of CRP and albumin (higher
in the control group), the two groups were comparable.
3.2. Outcomes in the Total Cohort. The mean age of the trial
population was 64 years (IQR 45–77), and 8,864 (52.8%)
were women. A total of 58 (0.3%) patients died within 24
hours, and 678 (4.0%) patients died within 30 days. The
proportion of patients who were discharged within 24 hours
of admittance was signiﬁcantly higher in the suPAR group
compared to the control group (50.2% (3,966 patients) vs.
48.6% (4,317 patients), absolute diﬀerence: 1.6% (95% CI:
0.08–3.12); P = 0 04). Baseline characteristics of patients
discharged within 24 hours compared to those of patients
with longer admissions are shown in Table S3. The mean
length of stay in the ED was 8.4 hours (SD 6.5). The median
suPAR level was signiﬁcantly lower in patients who were
discharged early: 3.5 ng/mL (IQR 2.6–4.8) vs. 4.9 ng/mL
(IQR 3.5–7.2) (P < 0 001). Patients discharged within 24
hours were signiﬁcantly younger and had a lower Charlson
score, creatinine, and CRP levels as well as higher albumin
and haemoglobin levels. Furthermore, the mean length of
hospital stay in the suPAR group was signiﬁcantly shorter
during the index admission compared to that in the control
group (4.3 days (SD 7.4) vs. 4.6 days (SD 9.4), diﬀerence
in hours: 6.5 (95% CI: 0.2–12.7); P = 0 04). In contrast,
the readmission rate within 30 days was signiﬁcantly
higher in the suPAR group (10.6% (839 patients) vs. 8.8%
(785 patients), absolute diﬀerence: 1.8% (95% CI: 0.9–2.7);
P < 0 001) (Table S1). Outcomes stratiﬁed according to
hospitals are reported in Table S4.
3.3. Death following Early Discharge. Baseline characteristics
at the index admission of patients discharged alive within
24 hours from the ED stratiﬁed by the presence (suPAR
group) or absence (control group) of suPAR are presented
in Table 1. There were signiﬁcant diﬀerences in the level of
albumin and haemoglobin. Death within 30 days occurred
in 52 patients (1.3%) in the suPAR group and in 77 patients
(1.8%) in the control group. None of the logistic regression
analyses revealed signiﬁcant diﬀerences in mortality between
groups: unadjusted (OR: 0.73, 95% CI: 0.51–1.04; P = 0 08) in
the suPAR group compared to the control group, adjusted
for age, sex, hospital, albumin, and haemoglobin (OR: 0.80,
95% CI: 0.54–1.19; P = 0 28), and fully adjusted model (OR:
0.74, 95 CI: 0.49–1.12; P = 0 16) (Table 2). Survival within
90 days following discharge is displayed in Figure 2.
3.4. Readmissions following Early Discharge. No signiﬁcant
diﬀerence was found in the readmission rate within 30 days
between the two groups of patients discharged within 24
7,898 patients with
suPAR measurement at
index admission
1,002 patients with no
suPAR measurement at
index admission
7,894 patients with no
suPAR measurement at
index admission
7 patients with suPAR
measurement at index
admission
16,801 patients in the full cohort of 
the TRIAGE III trial
8,900 patients admitted in the
intervention periods
7,901 patients admitted in the
control periods 
8,896 patients in the control group
7,905 patients in the suPAR group
Figure 1: Flow diagram of the study population. The ﬁgure shows the TRIAGE III study population and the composition of the groups, with
regard to the presence (suPAR group) and absence (control group) of suPAR in patients acutely admitted to two emergency departments
(EDs) studied in this study.
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hours. Readmission within 30 days occurred in 336 patients
(8.5%) vs. 331 patients (7.7%) (P = 0 18) for the suPAR
group and control group, respectively. The Cox model
with competing risks of death found no diﬀerence between
the groups in readmission within 30 days: HR: 1.1 (95%
CI: 0.95–1.29, P = 0 20).
3.5. Predictive Abilities of suPAR in Early Discharged Patients.
In patients discharged within 24 hours, the suPAR level dif-
fered between survivors and nonsurvivors at 30 days (median
3.5 ng/mL (2.6–4.7) vs. 8.5 ng/mL (6.7–11.8), P < 0 001).
No deaths occurred within 30 days in patients with a suPAR
level below 4.3 ng/mL. The AUC for predicting 30-day
mortality was 0.92 (95% CI 0.90–0.95). Stratifying suPAR
levels on quartiles revealed a good discriminative power espe-
cially in the upper quartile compared to the lower quartiles
(Figure S1). AUC comparison of age and analysed routine
biomarkers (blood levels of albumin, creatinine, CRP, and
haemoglobin) found age to be superior in predicting
mortality compared to routine biomarkers at 30 days, only
surpassed by suPAR (Figure 3 and Table 2).
A prediction model for 30-day mortality consisting of a
combination of biomarkers (containing blood levels of albu-
min, creatinine, CRP, and haemoglobin) was signiﬁcantly
Table 1: Characteristic of patients discharged from the emergency department within 24 hours based on the presence (suPAR group) or
absence (control group) of suPAR at the index admission.
suPAR (N = 3,966) Control (N = 4,317)
Hospital, no. of patients (%)
Bispebjerg Hospital 1,222 (30.8) 1,744 (40.4)
Herlev Hospital 2,744 (69.2) 2,573 (59.6)
Patients
Female sex—no. (%) 2,147 (54.1) 2,284 (52.9)
Age (years)—mean (SD) 53.6 (20.5) 53.5 (20.7)
Charlson score—mean (SD) 0.5 (1.2) 0.5 (1.2)
Blood levels of biomarkers, median (IQR)
Albumin (g/L) 41 (38–44) 41 (37– 44)∗
Creatinine (μmol/L) 72 (61–87) 73 (62–87)
CRP (mg/L) 3 (3–14) 3 (3–13)
Haemoglobin (mmol/L) 8.5 (7.9–9.2) 8.6 (7.9–9.2)∗
suPAR (ng/mL) 3.5 (2.6-4.8) n.a.
CRP: C-reactive protein; IQR: interquartile range; n.a.: not available; SD: standard deviation; suPAR: soluble urokinase plasminogen activator receptor. ∗P < 0 05.
Table 2: 30-day mortality of patients discharged within 24 hours. Groups were created based on the presence (suPAR group) or absence
(control group) of suPAR at the index admission.
Mortality, no. patients (%)
suPAR group 52 (1.3)
Control group 77 (1.8)
suPAR level at index admission (ng/mL)
Alive, median (IQR) 3.5 (2.6–4.7)
Dead, median (IQR) 8.5 (6.7–11.8)∗
Logistic regression models, OR (95% CI)
Unadjusted 0.73 (0.51–1.04)
Adjusted for age, sex, hospital, haemoglobin, and albumin level 0.80 (0.54–1.19)
Fully adjusted, all baseline variables 0.74 (0.49–1.12)
Area under the curve (95% CI)
Age 0.87 (0.83–0.91)
Albumin 0.86 (0.81–0.91)
Creatinine 0.73 (0.65–0.82)
CRP 0.81 (0.75–0.80)
Haemoglobin 0.76 (0.70–0.84)
suPAR 0.92 (0.90–0.95)
CI: conﬁdence interval; CRP: C-reactive protein; IQR: interquartile range; OR: odds ratio for the suPAR group compared to the control group; suPAR: soluble
urokinase plasminogen activator receptor. ∗P < 0 05.
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improved by adding suPAR (AUC 0.94 (95% CI 0.91–0.96),
P = 0 006), and suPAR predicted 30-day mortality equally
as good as the combined prediction model: AUC 0.92 (95%
CI 0.90–0.95) and AUC 0.92 (95% CI 0.89–0.95), respectively
(Figure S2). When using a combined outcome of readmission
or death within 30 days, the combined biomarker model with
an AUC of 0.92 (95% CI 0.89–0.95) was signiﬁcantly
improved when suPAR was added (AUC 0.94 (95% CI
0.91–0.96), P = 0 01).
4. Discussion
In this post hoc analysis study of a large cluster-randomized
trial, we found a signiﬁcantly higher proportion of patients
discharged within 24 hours from the ED and a signiﬁcantly
lower mean length of stay in the suPAR group compared to
the control group; however, these ﬁndings were accompanied
by a signiﬁcantly higher frequency of readmissions within 30
days in the suPAR group. In patients discharged within 24
hours, we observed no diﬀerence in all-cause mortality or
readmissions within 30 days according to whether suPAR
was available.
These analyses were aimed at evaluating the eﬀect of
using suPAR as a supportive tool when deciding on early dis-
charge from the ED as well as the prognostic value of suPAR
in predicting mortality. Our results indicate that a decision to
discharge based on the suPAR level is safe and feasible in
terms of the outcomes investigated. However, results of a
biomarker should be considered alongside other clinical
features in an overall assessment of the patient, as several
acute conditions require immediate attention and treatment,
regardless of the suPAR level. In this study, we observed that
availability of suPAR in the ED improved ﬂow parameters
(length of stay and number of discharges), which potentially
can reduce crowding, improve utilization of resources and
patient outcomes, and lead to savings in the health care
system. One potential drawback however is the increased
readmissions. The results presented here also demonstrate
superiority of suPAR as a prognostic biomarker compared
to other investigated biomarkers, including a combined
model of commonly used routine blood tests, in predicting
short-term mortality. The ED staﬀ was advised to consider
early discharge when the suPAR level was low and if the
other clinical ﬁndings did not contradict this. The high
AUC (0.92) of suPAR when predicting 30-day mortality
might reﬂect that the ED staﬀ was able to perform a more
accurate assessment of patients at risk of mortality, when
they had the suPAR level available.
The prognostic abilities of suPAR have been studied
before [3, 10–12], and the biomarker appears to be a potential
candidate for stratifying patients according to risk of mor-
tality and adverse events in emergency medicine [4, 5].
Previous studies have focused on high-risk patients (high
suPAR) and to a lesser extent investigated the clinical impact
of targeting patients with low suPAR levels. The nature of
suPAR is highly nonspeciﬁc, and plasma levels are associated
with a wide range of chronic conditions, cancer, and adverse
events during hospitalization [3, 25–31]. Due to these prop-
erties, a low suPAR level may be used to identify patients with
a good prognosis and at very low risk of short-term mortality
[3, 17]. This ability could be valuable when assessing a larger
number of patients in a short time at a busy ED. Improving
patient ﬂow by early discharge of low-risk patients, where
admission might not be necessary, will potentially beneﬁt
both patients in need of hospital treatment and low-risk
patients that can be discharged without being exposed to
the risks of hospitalization.
This study has several limitations. The interpretation
and generalizability of these results are limited as the study
92.5%
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suPAR
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Figure 2: Kaplan-Meier plot. The ﬁgure displays the survival of
patients discharged within 24 hours from emergency departments
stratiﬁed by the presence (suPAR group) or absence (control
group) of soluble urokinase plasminogen activator receptor at
admission. Log-rank test: P = 0 3.
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Figure 3: ROC curve for 30-day mortality. Receiver operating
characteristic (ROC) curves displaying the predictive abilities of
age, routine biomarkers, and soluble urokinase plasminogen
activator receptor (suPAR) regarding 30-day all-cause mortality.
Results were reported as the area under the curve with 95%
conﬁdence intervals.
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is based on post hoc analyses and was conducted at two
hospitals in the same region. These explorative results
must be conﬁrmed using a prospective approach focusing
on discharge. The TRIAGE III trial was originally designed
to detect changes in overall 10-month mortality and thus
overpowered in detecting diﬀerences in outcomes regard-
ing early discharge or length of stay. It should be consid-
ered that the observed diﬀerences are small, and whether
they can be considered clinically important depends on
the setting. Furthermore, the analyses presented here are
based on two groups consisting of patients with and with-
out a suPAR measured at admission, regardless of the allo-
cation in the original cluster randomization and not in
accordance with the intention-to-treat principle, which
might cause bias. This approach can be discussed, and
we do not know exactly why suPAR was not always
measured in the interventional period. There were small,
but signiﬁcant, diﬀerences in the Charlson score, albumin,
and CRP levels, which we do not consider clinically
important, and we found no diﬀerences in the baseline
characteristics or in mortality between patients without a
suPAR measurement in the intervention periods and
patients included in the control periods. However, this
approach might also be necessary to assess the impact of
using suPAR in clinical practice, as ED doctors will not
be able to guide interventions based on the biomarker
level without the result. We chose to assess outcomes
using the Danish registries as previous research has found
that registry-based outcomes are similar to those obtained
using adjudication committees [32]. Furthermore, when
assessing new initiatives in risk stratiﬁcation in the ED,
there are several other important outcomes that should
be assessed and reported (i.e., time to relevant treatment,
crowding, intensive care admissions, and unexpected
deterioration).
Although all outcomes presented here were included in
the original analysis plan [33], the ﬁndings in this secondary
study must be interpreted cautiously and be considered
hypothesis-generating. Thus, it will be reasonable to conduct
a future interventional study focusing on the negative predic-
tive value of suPAR with clearly deﬁned interventions, such
as recommendation for rapid discharge below a predeﬁned
cut-oﬀ value with subsequent follow-up at outpatient clinics
or by general practitioners.
5. Conclusion
These post hoc analyses demonstrate that the availability
of the prognostic biomarker suPAR may lead to reduced
length of stay and allow more discharges within 24 hours,
however, the overall readmittance rate was increased.
Patients who were discharged early, where suPAR was
available, had no increased risk of mortality or readmis-
sion within 30 days compared to those being in the standard
care. Usage of biomarker-based prognostic information for
clinical decisions is a concept that still needs additional
research before being implemented in routine practice but
has potential to improve patient health.
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sion. Table S3: patient characteristics at index admission for
patients discharged from the emergency department within
24 hours compared to patients with longer admissions. Table
S4: patient characteristics and outcomes stratiﬁed according
to hospital. Figure S1: survival of patients discharged within
24 hours from the emergency department stratiﬁed accord-
ing to suPAR quartiles measured at index admission. Log-
rank test: P < 0 001. Figure S2: ROC curve comparison of a
biomarker model and suPAR. Receiver operating character-
istic curves for 30-day all-cause mortality displaying predic-
tive abilities of a biomarker model (including levels of
albumin, creatinine, C-reactive protein, and haemoglobin),
the biomarker soluble urokinase plasminogen activator
receptor (suPAR), and the biomarker model combined with
suPAR. No suPAR: a biomarker model without suPAR;
suPAR included: a biomarker model including suPAR.
(Supplementary Materials)
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